Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05342545 · ClinicalTrials.gov registry record · NA
Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT05342545 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 400 participants.
The verdict
NCT05342545, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
While data from the National Health and Nutrition Examination Survey (NHANES) estimate that 36.9% of patients with diabetes have CKD, only approximately 10% of patients are aware of their kidney disease. In its 2020 Standards of Medical Care in Diabetes, the ADA recommends that all patients with type II diabetes (T2DM) undergo annual measurement of urine albumin-to-creatinine ratio (UACR). The National Kidney Foundation (NKF) has also proposed an update to the requirements for assessment of adults with diabetes including both an estimated glomerular filtration rate (eGFR) and uACR. The goal of accurately identifying patients with T2DM and CKD is to help providers intervene at an earlier stage of kidney impairment, improve renal outcomes, and reduce associated healthcare costs. Failure to adopt these guideline recommendations has widespread implications, including underestimation of the burden of CKD in the T2DM population, delays in diagnosis of renal impairment, and ultimately, underutilization of therapies that could improve clinical outcomes. This single-center, 400-patient, randomized controlled trial will assess the impact of an EPIC Best Practice Advisory (BPA; alert-based CDS tool) on guideline-directed assessment for CKD using UACR in patients with T2DM who have not had a UACR in the past year.
Interventions
- OTHER Alert-based computerized decision support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05342545
The ClinicalTrials.gov registry entry for NCT05342545 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alert-based computerized decision support is the first listed.
NCT05342545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05342545 about?
NCT05342545 is a clinical study titled "Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus". While data from the National Health and Nutrition Examination Survey (NHANES) estimate that 36.9% of patients with diabetes have CKD, only approximately 10% of patients are aware of their kidney disease. In its 2020 Standards of Medical Care in Diabetes, the ADA recommends that all patients with typ...
What is the current status of trial NCT05342545?
This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2022-12-01. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05342545?
The interventions under investigation include: Alert-based computerized decision support (OTHER).
Who is sponsoring clinical trial NCT05342545?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.